Nephros, Inc.
NEPHNephros, Inc. in brief
Nephros, Inc. is a listed company in the Medical Instruments industry, based in South Orange, New Jersey, USA. Its market value was $36 M on 30 October 2026, which makes it the 22,480th largest listed company in the world and the 3,991st largest in the USA on this site. In the year to December 2025 it had sales of $19 M and a net profit of $1 M, about 6 cents of profit for every dollar of sales. It employs about 36 people and Robert R. Banks Jr. is its chief executive. Its largest product and service lines by sales in 2025 were Royalty and Other Revenues (3%). Its shares trade under the symbol NEPH (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Nephros, Inc.
Nephros is a commercial-stage company that develops and markets high-performance water filtration solutions for points of use, with a core focus on medical-grade water filtration. Our medical filtration portfolio includes two product lines: infection control and dialysis water. The infection control segment features both microfilters (0.1 micron), which retain bacteria, and ultrafilters (0.005 micron), which retain bacteria, viruses, and endotoxins to address a broader spectrum of waterborne pathogens including and beyond Legionella and Pseudomonas. The dialysis segment consists exclusively of ultrafilters, extending the same microbial and endotoxin retention capabilities to the purification of water and bicarbonate concentrate used in dialysis treatment, where endotoxin control is especially critical. All of our medical-grade filters are FDA 510(k)-cleared as Class II medical devices—a distinguishing feature that affirms their validated safety and performance in critical-use environments. While these filters are widely used in healthcare settings, they have also been adopted across a range of other industries—including manufacturing, laboratories, aviation, and federal facilities—where water purity is essential to operational safety and compliance.
From the company's annual report filed with the US SEC: read the report
Nephros, Inc. timeline
- 2002
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- 💰Record revenue of $19 millionFY2025, the highest of the 8 years on record.
Events of Nephros, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,868 (Jan 2020) · #3,785 (Jan 2021) · #4,824 (Jan 2022) · #5,529 (Dec 2022) · #5,293 (Jul 2023) · #4,179 (Jan 2024) · #2,180 (Mar 2026) · #3,736 (Aug 2026) · #3,994 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- 18.7×
- Price / sales (TTM)
- 1.6×
- Price / book
- 3.5×
- Free cash flow yield
- -1.5%
- Net margin (TTM)
- 8.8%
- Operating margin
- 6.1%
- Return on equity
- 18.6%
- Liabilities / assets
- 25.2%
- Net debt
- $-4M
- Revenue growth
- +32.7%
- R&D / revenue
- 7.1%
- Revenue per employee
- $522 K
- Profit per employee
- $33 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $19M | +32.7% | $1M | $1M | 6.3% |
| Dec 2024 | $14M | -0.6% | $0M | $0M | 0.5% |
| Dec 2023 | $14M | +42.7% | $-2M | $-2M | -11.1% |
| Dec 2022 | $10M | -2.3% | $-4M | $-7M | -71.2% |
| Dec 2021 | $10M | +19.4% | $-3M | $-4M | -37.9% |
| Dec 2020 | $9M | -17.1% | $-4M | $-5M | -52.9% |
| Dec 2019 | $10M | +81.5% | $-3M | $-3M | -30.8% |
| Dec 2018 | $6M | — | $-3M | $-3M | -59.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $2M | — | — | $0.11 | — |
| Dec 2024 | $-0M | $0M | $-1M | $0.01 | — |
| Dec 2023 | $1M | $0M | $1M | $-0.15 | — |
| Dec 2022 | $-3M | $0M | $-3M | $-0.73 | — |
| Dec 2021 | $-1M | $0M | $-1M | $-0.41 | — |
| Dec 2020 | $-7M | $0M | $-7M | $-0.52 | — |
| Dec 2019 | $-2M | $0M | $-2M | $-0.45 | — |
| Dec 2018 | $-4M | — | — | $-0.50 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $6M (+18.1% on a year earlier), net income $1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 20268-KCurrent reportResults of operations
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Oct 14, 2026DEF 14AProxy statement
- Oct 13, 20268-KCurrent reportOther events
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 15, 20268-KCurrent reportRegulation FD disclosure
- May 7, 20268-KCurrent reportResults of operations
- May 7, 202610-QQuarterly report · period to Mar 2026
- Apr 30, 202610-K/AAnnual report (amended) · period to Dec 2025
- Mar 27, 20268-KCurrent reportRegulation FD disclosure
- Mar 12, 202610-KAnnual report · period to Dec 2025
Official filings of Nephros, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $19 M
- Operating income
- $1 M
- Net income
- $1 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $14 M
- Total liabilities
- $3 M
- Total equity
- $10 M
As of December-2025
Nephros, Inc. products and services
Search all products and services →Products (2)

Remove chlorine, taste, odor, cysts, chloramine, scale, soluble lead, and other particulates. Browse commercial water filtration solutions.

See Nephros dialysis water filters designed to maintain water quality, meet industry standards, and support safe, consistent patient care.
Services (6)

Nephros provides emergency water filtration support for bacteria-based water events and outbreaks, including suspected Legionella and other opportunistic waterborne pathogens. FDA Class II point-of-use fixture filters provide an immediate secondary barrier to support facility operations while longer-term mitigation plans are established.

Nephros provides expert installation and replacement support for infection control and commercial water filters to support proper installation, regulatory compliance, reliable system performance, and ongoing water safety.

Nephros provides ice machine audits for healthcare facilities to assess water sources, housings, tubing, maintenance practices, existing filtration, and opportunities to reduce waterborne contamination risks and improve water safety.

Nephros provides waterborne pathogen risk mitigation support through infection control filtration and water-quality education designed to reduce exposure to Legionella and other opportunistic waterborne pathogens in premise plumbing systems.

Nephros provides water management plan support for healthcare facilities through water system evaluations, facility audits, filtration solutions, and educational resources designed to support infection control, water safety, and operational continuity.

Nephros provides water safety and aesthetic improvement solutions using healthcare and commercial filtration technologies designed to address microbial contaminants and water-quality concerns such as taste, odor, cysts, scale, soluble lead, chlorine, chloramine, and E. Coli.
Top 36 institutional investors in Nephros, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Topline Capital Management, LLC | 535,698 | 0 (0.00%) | 4.93% | $2 M | Nov 16, 2026 |
| 2 | Massachusetts Institute Of Technology | 346,813 | New | 3.19% | $1 M | Nov 13, 2026 |
| 3 | Wexford Capital LP | 231,068 | -3,369,484 (-93.58%) | 2.13% | $1 M | Nov 13, 2026 |
| 4 | Vanguard Capital Management LLC | 198,643 | 0 (0.00%) | 1.83% | $1 M | Nov 13, 2026 |
| 5 | Johns Hopkins University | 187,857 | New | 1.73% | $1 M | Nov 16, 2026 |
| 6 | Meritage Group LP | 173,407 | New | 1.60% | $1 M | Nov 13, 2026 |
| 7 | Morgan Stanley | 123,915 | -5,000 (-3.88%) | 1.14% | $0 M | Nov 13, 2026 |
| 8 | Blackstone Inc. | 115,605 | New | 1.06% | $0 M | Nov 16, 2026 |
| 9 | Bard Associates Inc | 115,528 | -2,475 (-2.10%) | 1.06% | $0 M | Nov 13, 2026 |
| 10 | Renaissance Technologies LLC | 71,100 | -6,404 (-8.26%) | 0.65% | $0 M | Nov 12, 2026 |
| 11 | Geode Capital Management, LLC | 70,263 | 0 (0.00%) | 0.65% | $0 M | Nov 6, 2026 |
| 12 | Mesirow Financial Investment Management, Inc. | 60,000 | 0 (0.00%) | 0.55% | $0 M | Nov 5, 2026 |
| 13 | HighTower Advisors, LLC | 59,710 | 0 (0.00%) | 0.55% | $0 M | Nov 10, 2026 |
| 14 | Essex Investment Management Co LLC | 38,927 | 0 (0.00%) | 0.36% | $0 M | Oct 19, 2026 |
| 15 | Vanguard Fiduciary Trust Co | 36,901 | 0 (0.00%) | 0.34% | $0 M | Nov 13, 2026 |
| 16 | Blair William & Co/il | 36,249 | 0 (0.00%) | 0.33% | $0 M | Nov 10, 2026 |
| 17 | Northern Trust Corp | 28,266 | +11,560 (+69.20%) | 0.26% | $0 M | Nov 16, 2026 |
| 18 | Citadel Advisors LLC | 28,124 | -920 (-3.17%) | 0.26% | $0 M | Nov 16, 2026 |
| 19 | Dimensional Fund Advisors LP | 22,164 | 0 (0.00%) | 0.20% | $0 M | Nov 4, 2026 |
| 20 | BlackRock, Inc. | 18,003 | -819 (-4.35%) | 0.17% | $0 M | Nov 13, 2026 |
| 21 | State Street Corp | 15,698 | 0 (0.00%) | 0.14% | $0 M | Nov 12, 2026 |
| 22 | Mercer Global Advisors Inc /adv | 12,600 | +100 (+0.80%) | 0.12% | $0 M | Nov 16, 2026 |
| 23 | Goldman Sachs Group Inc | 11,908 | -928 (-7.23%) | 0.11% | $0 M | Nov 16, 2026 |
| 24 | Jasper Ridge Partners, L.P. | 11,560 | New | 0.11% | $0 M | Nov 13, 2026 |
| 25 | Elkhorn Partners Limited Partnership | 11,000 | 0 (0.00%) | 0.10% | $0 M | Nov 13, 2026 |
Show all 36: investors 26 to 36
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Cannell & Spears LLC | 11,000 | 0 (0.00%) | 0.10% | $0 M | Nov 12, 2026 |
| 27 | Bolton Securities Corporation | 7,192 | -19 (-0.26%) | 0.07% | $0 M | Nov 12, 2026 |
| 28 | Royal Bank Of Canada | 1,061 | +234 (+28.30%) | 0.01% | $0 M | Nov 16, 2026 |
| 29 | Wells Fargo & Company/mn | 200 | New | 0.00% | $0 M | Nov 16, 2026 |
| 30 | Osaic Holdings, Inc. | 175 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 31 | SBI Securities Co., Ltd. | 154 | +4 (+2.67%) | 0.00% | $0 M | Oct 22, 2026 |
| 32 | Tower Research Capital LLC (TRC) | 60 | New | 0.00% | $0 M | Nov 16, 2026 |
| 33 | Harbour Investments, Inc. | 50 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 34 | Jones Financial Companies Lllp | 31 | -196 (-86.34%) | 0.00% | $0 M | Nov 13, 2026 |
| 35 | Barclays PLC | 23 | -4 (-14.81%) | 0.00% | $0 M | Nov 6, 2026 |
| 36 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Nephros, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 130,901 | $0 M | 0.89% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 67,742 | $0 M | 0.46% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 33,707 | $0 M | 0.23% | <0.01% | +9.8% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 17,742 | $0 M | 0.12% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 11,571 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 9,528 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 4,811 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 3,085 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 3,337 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 2,725 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 2,462 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 2,333 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 2,332 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 1,419 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,080 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 409 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 16 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Nephros, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Arthur H. AmronDirector | Buy | +2,500 | $2.840 | $7 K | 169,637 | Form 4 |
| filed | Arthur H. AmronDirector | Buy | +5,000 | $2.995 | $15 K | 167,137 | Form 4 |
| filed | Arthur H. AmronDirector | Grant or award | +3,514 | — | — | 162,137 | Form 4 |
| filed | Oliver J. SpandowDirector | Grant or award | +3,916 | — | — | 126,797 | Form 4 |
| filed | Amron Holdings LLCDirector | Other | +17,749 | — | — | 158,623 | Form 4 |
| filed | Wexford GP LLC10% owner | Otherindirect | -3.36 M | — | — | 189,377 | Form 4 |
| filed | Amron Holdings LLCDirector | Otherindirect | +2,836 | — | — | 2,836 | Form 4 |
| filed | Wexford GP LLC10% owner | Otherindirect | -22,710 | $3.950 | $90 K | 166,667 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Nephros, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-05-08 13:57 UTC, code LUDP, resumed 14:02 UTC
- 2025-09-09 13:30 UTC, code LUDP, resumed 13:35 UTC
- 2025-06-20 19:53 UTC, code LUDP, resumed 20:00 UTC
Fails to deliver
- : 1,430 shares at $3.27
- : 144 shares at $4.47
- : 121 shares at $4.52
- : 1,509 shares at $4.55
- : 1,317 shares at $3.51
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Nephros, Inc. scorecard#
Passes 12 of the 21 checks that could be worked out: strongest in growth (5 of 6), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation4 of 6
- ✓P/E below its peers' median18.7×P/E 18.7× against Medical Instruments's median of 32.6×.
- ✓Price to book below its peers' median3.5×Price to book 3.5× against Medical Instruments's median of 3.9×.
- ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Medical Instruments's median of 3.0×.
- ✗Free cash flow yield above 5%-1.6%Free cash flow is -1.6% of the market value.
- ✓Earnings yield above the 10-year Treasury yield5.3%Earnings yield 5.3% against the 10-year Treasury's 5.15% on 2026-11-13.
- ✗The price assumes slower growth than the last three years'49.2%The price assumes 49.2% a year for ten years; revenue grew 23.5% a year over the last three.
Growth5 of 6
- ✓Revenue grew in the newest year32.7%Revenue up 32.7% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years23.5%23.5% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median23.5%23.5% a year against Medical Instruments's median of 5.0% (37 companies).
- ✓Earnings per share grew in the newest year0.11 vs 0.01Diluted EPS 0.11 in fiscal 2025 against 0.01 the year before (report's currency).
- ✓Net income higher than five years earlier$1 M$1 M in fiscal 2025 against -$5 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability2 of 5
- ✓Profitable in the newest year$1 MNet income $1 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median6.1%6.1% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%12.7%12.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier6.1%6.1% in fiscal 2025 against -43.5% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities4.0×Current ratio 4.05 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-6.09Z-score -6.09 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year3.5%Diluted shares up 3.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Nephros, Inc.'s statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 6.1% | 7.2% | |
| Net margin | 6.3% | 3.8% | |
| Return on equity | 12.7% | 3.5% | |
| Revenue growth, 3 years a year | 23.5% | 5.0% | |
| Revenue growth | 32.7% | 8.9% |
6of 8on the Piotroski tests of financial strength
Nephros, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 19+32.7%100% | 14−0.5%100% | 14+42.7%100% | 10.0−2.4%100% | 10r10+19.3%100% | 8.6−17.2%100% | 10+81.7%100% | 5.7+49.3%100% | 3.8+64.2%100% | 2.3—100% | |
| Cost of revenue | 7.2+31.7%38.1% | 5.4−6.8%38.4% | 5.8+11.2%41.0% | 5.2+14.4%52.6% | 4.6r4.7+25.7%44.9% | 3.6−14.2%42.6% | 4.3+71.1%41.1% | 2.5+63.7%43.7% | 1.5+47.9%39.8% | 1.0—44.2% | |
| Gross profit | 12+33.3%61.9% | 8.7+3.8%61.6% | 8.4+77.7%59.0% | 4.7−16.0%47.4% | 5.6r5.7+14.7%55.1% | 4.9−19.2%57.4% | 6.1+89.9%58.9% | 3.2+39.7%56.3% | 2.3+77.1%60.2% | 1.3—55.8% | |
| Research and development | 1.3+47.8%7.1% | 0.9+3.8%6.4% | 0.9−30.4%6.1% | 1.3−16.2%12.6% | 1.5r2.2−45.7%14.7% | 2.8−10.7%32.2% | 3.1+101%29.9% | 1.5+53.6%27.1% | 1.0−7.1%26.3% | 1.1—46.5% | |
| Selling, general and administrative | 9.0+17.2%47.9% | 7.7−13.9%54.2% | 8.9+17.4%62.6% | 7.6+5.5%76.1% | 7.2r7.7+11.3%70.4% | 6.5+5.7%75.5% | 6.1+35.5%59.2% | 4.5+37.0%79.4% | 3.3+15.6%86.6% | 2.9—123% | |
| Operating expenses | 10+20.2%55.8% | 8.7−12.8%61.6% | 10.0+10.3%70.2% | 9.1+2.0%90.9% | 8.9r10−3.3%87.0% | 9.2−0.6%107% | 9.2+48.6%89.4% | 6.2+37.6%109% | 4.5+8.5%119% | 4.2—179% | |
| Operating income | 1.1+19000%6.1% | 0.0—0.0% | −1.6—−11.2% | −4.3—−43.5% | −3.3r−4.3—−31.8% | −4.3—−49.9% | −3.2—−30.5% | −3.0—−53.0% | −2.2—−58.4% | −2.9—−124% | |
| Interest and finance income | — | — | — | — | — | — | — | 0.00.0%0.1% | 0.0−20.0%0.1% | 0.0—0.2% | |
| Interest expense and finance costs | 0.00.0%0.0% | 0.0−50.0%0.0% | 0.0−90.0%0.0% | 0.0−51.2%0.2% | 0.0−62.7%0.4% | 0.1−43.6%1.3% | 0.2+13.4%1.9% | 0.2−43.0%3.0% | 0.3+75.6%7.9% | 0.2—7.4% | |
| Other non-operating income (expense) | 0.1−27.7%0.3% | 0.1+361%0.6% | 0.0−69.0%0.1% | 0.1−87.6%0.6% | 0.5—4.6% | −0.3r−0.2—−2.9% | −0.1—−0.5% | −0.0—−0.6% | −0.1−1950%−1.9% | 0.0—0.2% | |
| Income before tax | 1.2+1255%6.4% | 0.1—0.6% | −1.6—−11.1% | — | — | −4.5—−52.9% | −3.4—−32.9% | −3.4—−60.1% | −2.6—−68.2% | −3.0—−131% | |
| Income tax | 0.0−20.0%0.1% | 0.0—0.1% | 0—0.0% | 0—0.0% | 0—0.0% | — | −0.2—−2.2% | −0.1—−1.6% | −1.8—−47.0% | — | |
| Income from discontinued operations | — | — | — | −2.8—−28.4% | −1.1—−10.6% | — | — | — | — | — | |
| Net income including minority interests | — | — | −1.6—−11.1% | −7.1—−71.2% | −3.9—−37.8% | — | −3.2—−30.8% | −3.3—−58.5% | −0.8—−21.2% | −3.0—−131% | |
| Minority interests' share of net income | — | — | — | 0.3+15.0%2.8% | 0.2—2.3% | — | 0.2+213%2.3% | 0.1—1.4% | — | — | |
| Net income attributable to shareholders | 1.2+1514%6.4% | 0.1—0.5% | −1.6—−11.1% | — | −3.9—−37.8% | −4.5—−52.9% | −3.2r−3.4—−30.8% | −3.4—−59.8% | −0.8—−21.2% | −3.0—−131% | |
| Earnings per share, basic | 0.11+1000%— | 0.01—— | -0.15—— | -0.73—— | -0.41—— | -0.52—— | -0.45—— | -0.50r-0.06—— | -0.02—— | -0.06—— | |
| Earnings per share, diluted | 0.11+1000%— | 0.01—— | -0.15—— | -0.73—— | -0.41—— | -0.52—— | -0.45—— | -0.50r-0.06—— | -0.02—— | -0.06—— | |
| Shares, weighted average (basic) | 11+0.8%— | 11+1.3%— | 10+0.9%— | 10+2.8%— | 10—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 11+3.5%— | 11+2.1%— | 10+0.9%— | 10+2.8%— | 10+10.3%— | 9.1+20.4%— | 7.5+10.2%— | 6.8r62−87.1%— | 53+9.0%— | 49—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.4+43.6%39.6% | 3.8−12.7%33.5% | 4.3+18.5%36.3% | 3.6−47.9%33.0% | 7.0−15.5%39.5% | 8.2+98.0%44.6% | 4.2−9.1%35.8% | 4.6+109%43.4% | 2.2+698%44.0% | 0.3—10.3% | |
| Receivables | 2.4+35.5%17.7% | 1.8+19.1%15.9% | 1.5+16.3%12.6% | 1.3−21.6%11.7% | 1.6+20.3%9.3% | 1.4+30.5%7.4% | 1.0−23.1%9.0% | 1.4r1.5+62.6%12.9% | 0.8+115%16.8% | 0.4—14.5% | |
| Inventory | 3.2+23.6%23.7% | 2.6+5.9%23.3% | 2.5−21.7%20.8% | 3.2−29.3%28.7% | 4.5r4.8−15.9%25.3% | 5.3+107%28.7% | 2.6+37.4%22.0% | 1.9+177%17.7% | 0.7+40.7%13.5% | 0.5—17.9% | |
| Other current assets | 0.2+24.6%1.3% | 0.1+7.6%1.3% | 0.1−29.8%1.1% | 0.2−9.2%1.7% | 0.2r0.2−12.7%1.2% | 0.2−54.9%1.3% | 0.5+90.6%4.5% | 0.3+225%2.6% | 0.1−10.5%1.7% | 0.1—3.5% | |
| Current assets | 11+35.2%82.3% | 8.3−1.3%74.0% | 8.4+1.7%70.9% | 8.3−39.4%75.1% | 14−10.0%77.2% | 15+82.6%81.9% | 8.3+1.5%71.4% | 8.2+115%77.4% | 3.8+201%76.4% | 1.3—47.2% | |
| Property, plant and equipment | 0.1−34.2%0.8% | 0.2+5.9%1.4% | 0.2+31.0%1.3% | 0.1+61.1%1.1% | 0.1r0.4−75.6%0.4% | 0.3+264%1.6% | 0.1−11.0%0.7% | 0.1+75.0%0.9% | 0.1−25.7%1.0% | 0.1—2.6% | |
| Right-of-use (leased) assets | 1.0−25.9%7.4% | 1.4−24.8%12.1% | 1.8+85.5%15.2% | 1.0+64.7%8.8% | 0.6r0.9−41.1%3.3% | 1.0r1.0−9.4%5.4% | 1.1—9.5% | — | — | — | |
| Goodwill | 0.80.0%5.6% | 0.80.0%6.8% | 0.80.0%6.4% | 0.80.0%6.9% | 0.80.0%4.3% | 0.80.0%4.1% | 0.8+1.5%6.5% | 0.7—7.1% | — | — | |
| Other intangible assets | 0.3−8.9%2.3% | 0.3−8.4%3.1% | 0.4−9.9%3.2% | 0.4−9.0%3.8% | 0.5r1.5−8.1%2.6% | 0.5−7.7%2.7% | 0.5−7.1%4.7% | 0.6−73.8%5.6% | 2.30.0%45.2% | 2.3—84.0% | |
| Total assets | 14+21.7%100% | 11−5.5%100% | 12+7.8%100% | 11−37.7%100% | 18−4.6%100% | 19+59.2%100% | 12+10.1%100% | 11+112%100% | 5.0+86.1%100% | 2.7—100% | |
| Accounts payable | 0.9+40.8%6.7% | 0.6−25.7%5.8% | 0.9+18.0%7.4% | 0.7−44.5%6.7% | 1.3+215%7.6% | 0.4−55.9%2.3% | 1.0+14.7%8.2% | 0.8−4.1%7.9% | 0.9+49.1%17.5% | 0.6—21.8% | |
| Current liabilities | 2.8+77.1%20.3% | 1.6−26.1%13.9% | 2.1+49.6%17.8% | 1.4−40.9%12.8% | 2.4+80.4%13.5% | 1.3−45.4%7.2% | 2.4−8.5%20.9% | 2.7+41.8%25.1% | 1.9+109%37.5% | 0.9—33.4% | |
| Lease liabilities (non-current) | 0.7−36.8%4.8% | 1.0−24.7%9.3% | 1.4+98.6%11.7% | 0.7r0.7+106%6.4% | 0.3r0.6−53.7%1.9% | 0.7r0.8−17.3%4.0% | 0.9—7.6% | — | — | — | |
| Total liabilities | 3.4+31.0%25.2% | 2.6−25.1%23.4% | 3.5+65.4%29.5% | 2.1−27.0%19.3% | 2.9−1.2%16.4% | 2.9−25.5%15.9% | 3.9+4.8%33.9% | 3.8+24.0%35.6% | 3.0+50.8%60.9% | 2.0—75.1% | |
| Retained earnings | −143—−1049% | −144—−1288% | −144—−1217% | −143—−1299% | −136—−769% | −132—−712% | −127—−1095% | −124—−1176% | −121—−2430% | −120—−4492% | |
| Shareholders' equity | — | — | 8.4+49.5%70.5% | 5.6−52.2%50.8% | 12−6.6%66.3% | 13+168%67.6% | 4.7+23.1%40.2% | 3.8+94.8%36.0% | 2.0+192%39.1% | 0.7—24.9% | |
| Minority interests | — | — | — | 3.3+7.7%29.9% | 3.1+0.1%17.3% | 3.1+1.2%16.5% | 3.0+0.5%25.9% | 3.0—28.4% | — | — | |
| Total equity | 10+18.8%74.8% | 8.6+2.7%76.6% | 8.4−5.9%70.5% | 8.9−39.8%80.7% | 15−5.3%83.6% | 16+103%84.1% | 7.7+13.1%66.1% | 6.8+249%64.4% | 2.0+192%39.1% | 0.7—24.9% | |
| Total liabilities and equity | 14+21.7%100% | 11−5.5%100% | 12+7.8%100% | 11−37.7%100% | 18−4.6%100% | 19+59.2%100% | 12+10.1%100% | 11+112%100% | 5.0+86.1%100% | 2.7—100% | |
| Shares outstanding | 11+0.9%— | 11+0.0%— | 11+2.4%— | 10+0.4%— | 10+3.9%— | 9.9+22.5%— | 8.1+12.2%— | 7.2r65−87.0%— | 55+11.1%— | 50—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.1+3.7%0.7% | 0.1−36.9%1.0% | 0.2−1.8%1.5% | 0.2+13.5%2.2% | 0.2r0.20.0%1.9% | 0.2+3.2%2.2% | 0.2+14.1%1.8% | 0.2−25.2%2.9% | 0.2+1047%5.7% | 0.0—0.8% | |
| Share-based compensation | 0.3+93.5%1.6% | 0.2−85.5%1.1% | 1.1+7.1%7.4% | 1.0−22.0%9.8% | 1.3+61.6%12.3% | 0.8−41.5%9.1% | 1.3+35.2%12.9% | 1.0+27.6%17.3% | 0.8+40.1%20.3% | 0.6—23.8% | |
| Cash from operating activities | 1.6—8.8% | −0.5−159%−3.5% | 0.8—5.8% | −3.2—−32.4% | −1.4—−13.9% | −6.9—−80.6% | −2.3—−22.0% | −3.7—−64.4% | −0.1—−2.0% | −2.1—−91.0% | |
| Capital expenditure | — | −0.1—−0.4% | −0.1—−0.5% | −0.1—−1.4% | −0.0—−0.4% | −0.2—−2.8% | −0.0—−0.1% | — | — | −0.0—−1.9% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | −0.1—−1.3% | −1.0—−17.4% | — | — | |
| Cash from investing activities | 0—0.0% | −0.1—−0.4% | −0.1—−0.5% | −0.1—−1.4% | −0.1—−0.8% | −0.2—−2.8% | −0.2—−1.5% | −1.0—−17.4% | — | −0.0—−1.9% | |
| Debt issued | — | — | — | — | — | 0.5—5.6% | — | — | — | — | |
| Shares issued | — | — | — | — | — | 11+475%134% | 2.0−47.3%19.3% | 3.8+220%66.4% | 1.2—31.0% | — | |
| Cash from financing activities | −0.0—−0.0% | −0.0—−0.0% | −0.1−332%−0.6% | 0.0−85.7%0.3% | 0.2−97.9%2.3% | 11+456%131% | 2.0−71.4%19.5% | 7.0+254%124% | 2.0+67.5%52.2% | 1.2—51.2% | |
| Change in cash | 1.6—8.7% | −0.5−181%−3.9% | 0.7—4.7% | −3.3—−33.5% | −1.3−131%−12.5% | 4.1—47.7% | −0.4−117%−4.0% | 2.4—42.0% | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 22+20.4%100% | 5.6+18.0%100% | 6.0+36.2%100% | 5.2+6.9%100% | 4.7*+22.2%100% | 4.8+35.4%100% | 4.4+35.9%100% | 4.9+38.5%100% | 3.9*+18.9%100% | 3.5—100% | 3.3—100% | 3.5—100% | 3.3*—100% | |
| Cost of revenue | 8.5+29.2%39.5% | 2.3+26.3%41.6% | 2.0+22.6%33.1% | 2.2+28.8%42.6% | 2.0*+41.1%41.6% | 1.8+35.1%38.8% | 1.6+21.2%36.8% | 1.7+29.1%35.3% | 1.4*+13.1%36.0% | 1.4—38.9% | 1.3—41.2% | 1.3—37.9% | 1.2*—37.9% | |
| Gross profit | 13+15.2%60.5% | 3.3+12.7%58.4% | 4.0+44.0%66.9% | 3.0−5.1%57.4% | 2.8*+11.6%58.4% | 2.9+35.6%61.2% | 2.8+46.2%63.2% | 3.2+44.2%64.7% | 2.5*+22.5%64.0% | 2.1—61.1% | 1.9—58.8% | 2.2—62.1% | 2.0*—62.1% | |
| Research and development | 1.4+20.2%6.7% | 0.3−2.1%5.9% | 0.4+17.7%6.1% | 0.3+17.3%6.6% | 0.4*+56.7%8.4% | 0.3+79.8%7.1% | 0.3+22.4%7.0% | 0.3+39.2%6.0% | 0.3*+21.2%6.5% | 0.2—5.3% | 0.3—7.8% | 0.2—6.0% | 0.2*—6.4% | |
| Selling, general and administrative | 9.7+13.1%44.9% | 2.4+8.8%43.1% | 2.4+9.9%40.2% | 2.5+11.8%48.4% | 2.3*+23.7%49.0% | 2.2+29.5%46.8% | 2.2+13.4%49.8% | 2.3+5.2%46.2% | 1.9*−22.4%48.4% | 1.7—48.9% | 1.9—59.7% | 2.1—60.8% | 2.4*—74.1% | |
| Operating expenses | 11+13.6%52.1% | 2.8+7.1%49.5% | 2.8+10.4%46.8% | 2.9+11.9%55.6% | 2.7*+27.1%58.0% | 2.6+33.9%54.6% | 2.5+14.3%57.6% | 2.6+8.4%53.1% | 2.2*−19.2%55.8% | 1.9—55.2% | 2.2—68.5% | 2.4—67.8% | 2.7*—82.1% | |
| Operating income | 1.8+26.6%8.5% | 0.5+59.6%8.9% | 1.2+389%20.2% | 0.1−82.9%1.9% | 0.0*−94.3%0.4% | 0.3+52.4%6.6% | 0.2—5.6% | 0.6—11.6% | 0.3*—8.2% | 0.2—5.9% | −0.3—−9.7% | −0.2—−5.7% | −0.6*—−19.9% | |
| Interest expense and finance costs | — | 0*—0.0% | 0.00.0%0.0% | — | 0*—0.0% | 0*—0.0% | 0.0—0.0% | — | 0*−100%0.0% | 0*—0.0% | 0*—0.0% | 0.0—0.0% | 0.0*—0.0% | |
| Other non-operating income (expense) | 0.1+50.8%0.4% | 0.0−57.7%0.2% | −0.0—−0.0% | 0.0—0.8% | 0.0*−6.4%0.9% | 0.0—0.5% | −0.0−107%−0.0% | −0.0−126%−0.2% | 0.0*—1.2% | −0.0—−0.7% | 0.0—0.9% | 0.0—0.9% | −0.0*—−0.2% | |
| Income before tax | — | 0.5+50.6%9.1% | 1.2+392%20.1% | — | 0.1*−83.0%1.3% | 0.3+85.8%7.1% | 0.2—5.6% | — | 0.4*—9.4% | 0.2—5.2% | −0.3—−8.9% | — | — | |
| Income tax | 0.0−51.9%0.1% | 0*−100%0.0% | 0.0+44.4%0.2% | 0—0.0% | 0*−100%0.0% | 0.0—0.1% | 0.0—0.2% | 0—0.0% | 0.0*—0.4% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | |
| Net income including minority interests | — | — | — | — | — | — | — | — | — | — | — | — | −0.7*—−20.1% | |
| Net income attributable to shareholders | 1.9+29.0%8.9% | 0.5+51.9%9.1% | 1.2+405%19.9% | 0.1−74.9%2.7% | 0.1*−82.2%1.3% | 0.3+84.2%7.1% | 0.2—5.4% | 0.6—11.4% | 0.3*—9.0% | 0.2—5.2% | −0.3—−8.9% | −0.2—−4.8% | −0.7*—−20.1% | |
| Earnings per share, basic | — | 0.05+66.7%— | 0.11+450%— | 0.01−80.0%— | — | 0.03+50.0%— | 0.02—— | 0.05—— | — | 0.02—— | -0.03—— | -0.02—— | — | |
| Earnings per share, diluted | — | 0.05+66.7%— | 0.11+450%— | 0.01−80.0%— | — | 0.03+50.0%— | 0.02—— | 0.05—— | — | 0.02—— | -0.03—— | -0.02—— | — | |
| Shares, weighted average (basic) | 11+2.4%— | 11+2.4%— | 11+2.4%— | 11+0.5%— | — | 11+0.6%— | 11+0.9%— | 11+0.9%— | — | 11—— | 11—— | 11—— | — | |
| Shares, weighted average (diluted) | 11+1.5%— | 11+1.5%— | 11+2.8%— | 11+3.5%— | — | 11+4.3%— | 11+2.9%— | 11+1.1%— | — | 11—— | 11—— | 11—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.5—29.7% | 4.5−12.1%29.7% | 4.7−7.4%29.8% | 4.0−1.5%29.1% | 5.4+43.6%39.6% | 5.2+110%39.0% | 5.1+64.7%41.4% | 4.1+12.3%34.6% | 3.8−12.7%33.5% | 2.5—23.7% | 3.1—27.7% | 3.6—31.8% | 4.3—36.3% | |
| Receivables | 3.6—23.4% | 3.6+34.6%23.4% | 4.1+101%26.0% | 3.5+31.5%25.5% | 2.4+35.5%17.7% | 2.7+57.4%20.1% | 2.0+8.6%16.7% | 2.7+76.4%22.7% | 1.8+19.1%15.9% | 1.7—16.3% | 1.9—16.9% | 1.5—13.3% | 1.5—12.6% | |
| Inventory | 5.0—32.4% | 5.0+80.9%32.4% | 4.5+103%28.8% | 3.6+85.2%26.2% | 3.2+23.6%23.7% | 2.7−11.6%20.7% | 2.2−20.2%18.3% | 2.0−29.7%16.6% | 2.6+5.9%23.3% | 3.1—29.8% | 2.8—25.3% | 2.8—24.3% | 2.5—20.8% | |
| Other current assets | 0.2—1.1% | 0.2+27.9%1.1% | 0.3+12.8%1.6% | 0.3+20.7%2.5% | 0.2+24.6%1.3% | 0.1+24.8%1.0% | 0.2+37.6%1.9% | 0.3+40.0%2.4% | 0.1+7.6%1.3% | 0.1—1.0% | 0.2—1.5% | 0.2—1.8% | 0.1—1.1% | |
| Current assets | 13—86.6% | 13+23.8%86.6% | 14+42.0%86.2% | 11+27.8%83.3% | 11+35.2%82.3% | 11+45.5%80.8% | 9.6+20.8%78.2% | 9.0+10.6%76.3% | 8.3−1.3%74.0% | 7.4—70.8% | 7.9—71.4% | 8.1—71.2% | 8.4—70.9% | |
| Property, plant and equipment | 0.1—0.5% | 0.1−39.5%0.5% | 0.1−36.6%0.5% | 0.1−33.6%0.7% | 0.1−34.2%0.8% | 0.1−31.2%0.9% | 0.1−29.6%1.1% | 0.1+0.7%1.2% | 0.2+5.9%1.4% | 0.2—1.7% | 0.2—1.7% | 0.1—1.2% | 0.2—1.3% | |
| Right-of-use (leased) assets | 0.7—4.7% | 0.7−33.9%4.7% | 0.8−30.9%5.2% | 0.9−28.1%6.6% | 1.0−25.9%7.4% | 1.1−23.9%8.3% | 1.2−23.7%9.7% | 1.3−24.4%10.8% | 1.4−24.8%12.1% | 1.4—13.8% | 1.6—14.0% | 1.7—14.7% | 1.8—15.2% | |
| Goodwill | 0.8—5.0% | 0.80.0%5.0% | 0.80.0%4.8% | 0.80.0%5.5% | 0.80.0%5.6% | 0.80.0%5.7% | 0.80.0%6.2% | 0.80.0%6.4% | 0.80.0%6.8% | 0.8—7.3% | 0.8—6.8% | 0.8—6.6% | 0.8—6.4% | |
| Other intangible assets | 0.3—1.9% | 0.3−9.8%1.9% | 0.3−9.6%1.9% | 0.3−9.1%2.2% | 0.3−8.9%2.3% | 0.3−8.7%2.5% | 0.3−8.5%2.7% | 0.3−8.6%2.9% | 0.3−8.4%3.1% | 0.4—3.4% | 0.4—3.3% | 0.4—3.3% | 0.4—3.2% | |
| Total assets | 15—100% | 15+15.5%100% | 16+28.8%100% | 14+17.1%100% | 14+21.7%100% | 13+27.5%100% | 12+10.3%100% | 12+3.2%100% | 11−5.5%100% | 10—100% | 11—100% | 11—100% | 12—100% | |
| Accounts payable | 0.9—5.6% | 0.9−9.2%5.6% | 2.0+211%12.5% | 1.5+163%10.6% | 0.9+40.8%6.7% | 0.9+135%7.1% | 0.6−45.5%5.2% | 0.6−50.0%4.7% | 0.6−25.7%5.8% | 0.4—3.8% | 1.2—10.4% | 1.1—9.8% | 0.9—7.4% | |
| Current liabilities | 2.4—15.7% | 2.4−2.4%15.7% | 3.3+88.7%21.2% | 2.5+66.5%18.3% | 2.8+77.1%20.3% | 2.5+133%18.6% | 1.8−9.2%14.5% | 1.5−21.3%12.9% | 1.6−26.1%13.9% | 1.1—10.2% | 2.0—17.6% | 1.9—16.9% | 2.1—17.8% | |
| Lease liabilities (non-current) | 0.3—2.2% | 0.3−55.2%2.2% | 0.5−47.6%2.9% | 0.6−41.7%4.0% | 0.7−36.8%4.8% | 0.8−33.0%5.7% | 0.9−29.8%7.0% | 1.0−27.1%8.1% | 1.0−24.7%9.3% | 1.1—10.9% | 1.2—11.0% | 1.3—11.4% | 1.4—11.7% | |
| Total liabilities | 2.8—18.0% | 2.8−14.9%18.0% | 3.8+43.8%24.1% | 3.1+24.4%22.4% | 3.4+31.0%25.2% | 3.2+46.5%24.5% | 2.6−16.7%21.6% | 2.5−23.1%21.1% | 2.6−25.1%23.4% | 2.2—21.3% | 3.2—28.6% | 3.2—28.3% | 3.5—29.5% | |
| Retained earnings | −141—−923% | −141—−923% | −142—−899% | −143—−1037% | −143—−1049% | −143—−1081% | −144—−1172% | −144—−1221% | −144—−1288% | −145—−1393% | −145—−1305% | −145—−1266% | −144—−1217% | |
| Shareholders' equity | — | — | — | — | — | — | — | — | — | — | — | — | 8.4—70.5% | |
| Total equity | 13—82.0% | 13+25.4%82.0% | 12+24.7%75.9% | 11+15.2%77.6% | 10+18.8%74.8% | 10+22.4%75.5% | 9.6+21.1%78.4% | 9.3+13.6%78.9% | 8.6+2.7%76.6% | 8.2—78.7% | 7.9—71.4% | 8.2—71.7% | 8.4—70.5% | |
| Total liabilities and equity | 15—100% | 15+15.5%100% | 16+28.8%100% | 14+17.1%100% | 14+21.7%100% | 13+27.5%100% | 12+10.3%100% | 12+3.2%100% | 11−5.5%100% | 10—100% | 11—100% | 11—100% | 12—100% | |
| Shares outstanding | 11—— | 11+2.3%— | 11+2.4%— | 11+2.3%— | 11+0.9%— | 11+0.8%— | 11+0.5%— | 11+0.5%— | 11+0.0%— | 11—— | 11—— | 11—— | 11—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−16.2%0.6% | 0.0−14.7%0.5% | 0.0−17.1%0.5% | 0.0−25.6%0.6% | 0.0*−5.9%0.7% | 0.00.0%0.7% | 0.0+2.9%0.8% | 0.0+18.2%0.8% | 0.0*−33.3%0.9% | 0.0—1.0% | 0.0—1.0% | 0.0—0.9% | 0.1*—1.6% | |
| Share-based compensation | 0.3−6.8%1.2% | 0.1*−14.3%1.1% | 0.1*−14.1%1.0% | 0.1−21.1%1.2% | 0.1*+27.4%1.7% | 0.1*+7.7%1.5% | 0.1*+103%1.6% | 0.1—1.6% | 0.1*−84.1%1.6% | 0.1*—1.8% | 0.0*—1.1% | −0.0—−0.3% | 0.4*—12.0% | |
| Cash from operating activities | −0.9−133%−4.2% | −0.2*−252%−2.7% | 0.7*−31.5%11.3% | −1.7−619%−32.1% | 0.2*−82.4%4.9% | 0.1*—2.1% | 1.0*—22.5% | 0.3—6.6% | 1.3*—33.7% | −0.6*—−17.7% | −0.5*—−15.4% | −0.7—−19.1% | −0.2*—−7.3% | |
| Capital expenditure | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | — | |
| Cash from investing activities | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | — | |
| Cash from financing activities | 0.3—1.3% | −0.0*—−0.0% | −0.0*—−0.0% | 0.3—5.5% | −0.0*—−0.0% | −0.0*—−0.0% | −0.0*—−0.0% | −0.0—−0.0% | −0.0*—−0.0% | 0*—0.0% | −0.0*—−0.1% | −0.0—−0.1% | −0.0*—−0.1% | |
| Change in cash | −0.6−123%−2.9% | −0.2*−256%−2.7% | 0.7*−31.6%11.3% | −1.4−531%−26.5% | 0.2*−82.4%4.8% | 0.1*—2.0% | 1.0*—22.5% | 0.3—6.6% | 1.3*—33.7% | −0.6*—−17.7% | −0.6*—−17.0% | −0.7—−19.1% | −0.3*—−9.7% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Nephros, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$18 M97%+30%
- Royalty and Other Revenues$1 M3.0%+331%
- Service(total)$1 M2.8%+550%
- Other Revenue$0 M0.1%-50%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Nephros, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Andrew Astor | $627 K | $1.2 M | $323 K | $25 |
| 2024Andrew Astor | $410 K | −$176 K | $149 K | $25 |
| 2023Robert R. Banks Jr. | $695 K | $1.3 M | $168 K | $40 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Nephros, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 1 · Agreement ended 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2021 | $1 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| May 2019 | $2 M | Private placement after listing | $2 to $10 million | 12 | equity | SEC |
| Apr 2018 | $3 M | Private placement after listing | $2 to $10 million | 13 | equity | SEC |
| Mar 2017 | $2 M | Private placement after listing | $2 to $10 million | 19 | equity, options | SEC |
| Jul 2015 | $1 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| May 2015 | $1 M | Private placement after listing | Under $2 million | 26 | equity, options | SEC |
| Jul 2009 | $1 M | No. 1 | Under $2 million | 8 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Nephros, Inc. compares in Medical Instruments
- Market cap$36 M · higher than 6% of 116
- Revenue$19 M · higher than 8% of 120
- Net margin8.8% · higher than 50% of 114
- Revenue growth32.7% · higher than 96% of 49
- P/E ratio18.7× · lower than 72% of 68
- Price / sales1.6× · lower than 80% of 85
- Price / book3.5× · lower than 51% of 84
- FCF yield-1.6% · higher than 29% of 39
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Nephros, Inc.🇺🇸 | $36 M | 18.7× | 8.8% | +32.7% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Nephros, Inc.? Verify and update this profile — free
Show Nephros, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.